Newborn bloodspot screening for lysosomal storage disorders

Journal of Pediatrics

Volumn 159, Issue 1, 2011, Pages

  Zhou, Hui ^a   Fernhoff, Paul ^b   Vogt, Robert F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ENZYME;

ADRENOLEUKODYSTROPHY; BLOOD EXAMINATION; EARLY DIAGNOSIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; FABRY DISEASE; GAUCHER DISEASE; GENE REPLACEMENT THERAPY; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC RISK; GLOBOID CELL LEUKODYSTROPHY; GLYCOGEN STORAGE DISEASE TYPE 2; HETEROZYGOTE; HUMAN; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; NEWBORN; NEWBORN SCREENING; NIEMANN PICK DISEASE; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 79958698842     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2011.02.026     Document Type: Article

References (72)

1. Wilcox WR. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr 2004;144: S3-14.
2. Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 2004;50:1785-96. (Pubitemid 39298007)
3. Wang D, Eadala B, Sadilek M, Chamoles NA, Turecek F, Scott CR, et al. Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem 2005;51:898-900. (Pubitemid 40577928)
4. Zhang XK, Elbin CS, Chuang WL, Cooper SK, Marashio CA, Beauregard C, et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem 2008;54:1725-8.
5. Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010;285:20423-7.
6. Wenger DA, Coppola S, Liu SL. Insights into the diagnosis and treatment of lysosomal storage diseases. Arch Neurol 2003;60:322-8. (Pubitemid 36314356)
7. Parkinson-Lawrence EJ, Shandala T, Prodoehl M, Plew R, Borlace GN, Brooks DA. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology (Bethesda) 2010;25:102-15.
8. Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E. Lysosomal storage disorders in the newborn. Pediatrics 2009;123:1191-207.
9. Smid BE, Aerts JM, Boot RG, Linthorst GE, Hollak CE. Pharmacological small molecules for the treatment of lysosomal storage disorders. Expert Opin Investig Drugs 2010;19:1367-79.
10. Beck M. Therapy for lysosomal storage disorders. IUBMB Life 2010;62:33-40.
11. Lim-Melia ER, Kronn DF. Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann 2009;38:448-55.
12. Platt FM, Jeyakumar M. Substrate reduction therapy. Acta Paediatr Suppl 2008;97:88-93. (Pubitemid 351421298)
13. Yu Z, Sawkar AR, Kelly JW. Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J 2007;274:4944-50. (Pubitemid 47481193)
14. Brooks DA, Muller VJ, Hopwood JJ. Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 2006;12:367-73. (Pubitemid 44149238)
15. Sands MS, Haskins ME. CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr Suppl 2008;97:22-7. (Pubitemid 351421300)
16. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Twenty years of gene therapy for SCID. Nat Immunol 2010;11:457-60.
17. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009;326:818-23.
18. Cartier N, Aubourg P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol 2010;20:857-62.
19. Naldini L. Medicine: a comeback for gene therapy. Science 2009;326:805-6.
20. Impact of expanded newborn screening: United States, 2006. MMWR Morb Mortal Wkly Rep 2008;57:1012-5.
21. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43.
22. Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 1990;13:321-4. (Pubitemid 20338872)
23. Frazier DM, Millington DS, McCandless SE, Koeberl DD, Weavil SD, Chaing SH, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997-2005. J Inherit Metab Dis 2006;29:76-85.
24. Newborn screening: toward a uniform screening panel and system: executive summary. Pediatrics 2006;117:S296-307.
25. Sweetman L, Millington DS, Therrell BL, Hannon WH, Popovich B, Watson MS, et al. Naming and counting disorders (conditions) included in newborn screening panels. Pediatrics 2006;117:S308-14.
26. Newborn screening: toward a uniform screening panel and system. Genet Med 2006;8(Suppl 1):1S-252.
27. Perrin JM, Knapp AA, Browning MF, Comeau AM, Green NS, Lipstein EA, et al. An evidence development process for newborn screening. Genet Med 2010;12:131-4.
28. Calonge N, Green NS, Rinaldo P, Lloyd-Puryear M, Dougherty D, Boyle C, et al. Committee report: method for evaluating conditions nominated for population-based screening of newborns and children. Genet Med 2010;12:153-9.
29. Kemper AR, Knapp AA, Green NS, Comeau AM, Metterville DR, Perrin JM. Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genet Med 2010;12:539-43.
30. Advisory Committee on Heritable Disorders in Newborns and Children. Available at: http://www.hrsa.gov/heritabledisorderscommittee/meetings/ 2008october/minutesoct2008.htm. Accessed October 17, 2010.
31. Advisory Committee on Heritable Disorders in Newborns and Children. Available at: http://www.hrsa.gov/heritabledisorderscommittee/meetings/ 2009september/summary.htm. Accessed October 17, 2010.
32. Advisory Committee on Heritable Disorders in Newborns and Children. Available at: http://www.hrsa.gov/heritabledisorderscommittee/correspondence/ feb2010letter.htm. Accessed October 17, 2010.
33. Advisory Committee on Heritable Disorders in Newborns and Children. Available at: http://www.hrsa.gov/heritabledisorderscommittee/correspondence/ response5-21-2010.pdf. Accessed October 17, 2010.
34. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001;308:195-6. (Pubitemid 32537628)
35. Chamoles NA, Blanco M, Gaggioli D. Diagnosis of alpha-L-iduronidase deficiency in dried blood spots on filter paper: the possibility of newborn diagnosis. Clin Chem 2001;47:780-1. (Pubitemid 32275835)
36. Chamoles NA, Blanco M, Gaggioli D, Casentini C. Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002;318:133-7. (Pubitemid 34195597)
37. Chamoles NA, Blanco M, Gaggioli D, Casentini C. Gaucher and Niemann-Pick diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002;317:191-7. (Pubitemid 34114035)
38. Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem 2001;47:2098-102. (Pubitemid 33108873)
39. Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta 2004;347:97-102. (Pubitemid 39099610)
40. Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008;122:e39-45.
41. Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 2009;30:1397-405.
42. Labrousse P, Chien YH, Pomponio RJ, Keutzer J, Lee NC, Akmaev VR, et al. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab 2010;99:379-83.
43. Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009;124:e1116-25.
44. Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2009;2:450-6.
45. Gerber SA, Scott CR, Turecek F, Gelb MH. Direct profiling of multiple enzyme activities in human cell lysates by affinity chromatography/electrospray ionization mass spectrometry: application to clinical enzymology. Anal Chem 2001;73:1651-7. (Pubitemid 32862427)
46. Li Y, Brockmann K, Turecek F, Scott CR, Gelb MH. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem 2004;50:638-40. (Pubitemid 38297317)
47. Wang D, Wood T, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem 2007;53:137-40. (Pubitemid 46047775)
48. Duffey TA, Khaliq T, Scott CR, Turecek F, Gelb MH. Design and synthesis of substrates for newborn screening of Maroteaux-Lamy and Morquio A syndromes. Bioorg Med Chem Lett 2010;20:5994-6.
49. Duffey TA, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome). Anal Chem 2010;82:9587-91.
50. Zhang XK, Elbin CS, Turecek F, Scott R, Chuang WL, Keutzer JM, et al. Multiplex lysosomal enzyme activity assay on dried blood spots using tandem mass spectrometry. Methods Mol Biol 2010;603:339-50.
51. De Jesus VR, Zhang XK, Keutzer J, Bodamer OA, Muhl A, Orsini JJ, et al. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. Clin Chem 2009;55:158-64.
52. Orsini JJ, Morrissey MA, Slavin LN, Wojcik M, Biski C, Martin M, et al. Implementation of newborn screening for Krabbe disease: population study and cutoff determination. Clin Biochem 2009;42:877-84.
53. Dajnoki A, Muhl A, Fekete G, Keutzer J, Orsini J, Dejesus V, et al. Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. Clin Chem 2008;54:1624-9.
54. Dajnoki A, Fekete G, Keutzer J, Orsini JJ, De Jesus VR, Chien YH, et al. Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry. Clin Chim Acta 2010;411:1428-31.
55. la Marca G, Casetta B, Malvagia S, Guerrini R, Zammarchi E. New strategy for the screening of lysosomal storage disorders: the use of the online trapping-and-cleanup liquid chromatography/mass spectrometry. Anal Chem 2009;81:6113-21.
56. Kasper DC, Herman J, De Jesus VR, Mechtler TP, Metz TF, Shushan B. The application of multiplexed, multi-dimensional ultra-high-performance liquid chromatography/tandem mass spectrometry to the highthroughput screening of lysosomal storage disorders in newborn dried bloodspots. Rapid Commun Mass Spectrom 2010;24:986-94.
57. Duffey TA, Bellamy G, Elliott S, Fox AC, Glass M, Turecek F, et al. A tandem mass spectrometry triplex assay for the detection of Fabry, Pompe, and mucopolysaccharidosis-I (Hurler). Clin Chem 2010;56:1854-61.
58. Duffner PK, Caggana M, Orsini JJ, Wenger DA, Patterson MC, Crosley CJ, et al. Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 2009;40:245-55.
59. Steiner RD. Commentary on: "Newborn screening for Krabbe Disease: the New York state model" and "The long-term outcomes of presymptomatic infants transplanted for Krabbe disease." A report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med 2009;11:411-3.
60. Wenger DA, Rafi MA, Luzi P. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. Hum Mutat 1997;10:268-79. (Pubitemid 27430501)
61. Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab 2006;88:307-14. (Pubitemid 44107765)
62. Matern D. Newborn screening for lysosomal storage disorders. Acta Paediatr Suppl 2008;97:33-7. (Pubitemid 351421295)
63. Tomatsu S, Montano AM, Oguma T, Dung VC, Oikawa H, de Carvalho TG, et al. Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry. J Inherit Metab Dis 2010. Epub ahead of print.
64. Brown JR TN, Le S, Glass C, Dickson P, Crawford BE. Glycan-Based Biomarkers for Lysosomal Storage Disease: The Sensi-Pro Assay. Available at: http://www.zacharon.com/PDFs/SensiProPosterWORLD.pdf. Lysosomal Disease Network WORLD Symposium 2010.
65. Tomatsu S, Montano AM, Oguma T, Dung VC, Oikawa H, de Carvalho TG, et al. Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. J Inherit Metab Dis 2010;33:141-50.
66. Tomatsu S, Montano AM, Oguma T, Dung VC, Oikawa H, Gutierrez ML, et al. Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. Mol Genet Metab 2010;99:124-31.
67. Hubbard WC, Moser AB, Liu AC, Jones RO, Steinberg SJ, Lorey F, et al. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 2009;97:212-20.
68. Millington DS, Sista R, Eckhardt A, Rouse J, Bali D, Goldberg R, et al. Digital microfluidics: a future technology in the newborn screening laboratory? Semin Perinatol 2010;34:163-9.
69. American College of Medical Genetics Newborn Screening ACT Sheets. Available at: http://www.acmg.net/AM/Template.cfm?Section=NBS-ACT-Sheets-and- Algorithms-Table&Template=/CM/HTMLDisplay.cfm&ContentID=5072. Accessed October 28, 2010.
70. Genzyme Corporate Gaucher, Fabry, MPS I and Pompe Registries. Available at: https://www.lsdregistry.net/. Accessed October 28, 2010.
71. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia 2010;24:285-97.
72. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007;120:405-18. (Pubitemid 47219512)